| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4001848 | American Journal of Ophthalmology | 2016 | 21 Pages |
Abstract
After anti-VEGF therapy, significant improvement in VA was observed for low-risk CFH genotypes and subjects with a low risk score. There was a statistically significant reduction in central foveal thickness overall, and subjects with a low CFH risk score improved more than the high-risk group.
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Anjali R. Shah, Steven Williams, Caroline R. Baumal, Bernard Rosner, Jay S. Duker, Johanna M. Seddon,